[1] |
HE Xueru, LI Ying, MA Yinling, FU Yuhao, XUN Xuejiao, DONG Zhanjun.
Pharmacokinetic interaction study between sorafenib and dapagliflozin in rats
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 498-507.
|
[2] |
HE Xueru, FU Yuhao, XUN Xuejiao, CUI Yanjun, DONG Zhanjun.
Advances in uridine diphosphate glucuronosyltransferase-mediated drug interactions with tyrosine kinase inhibitors
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 936-945.
|
[3] |
LIU Lu, CHEN Xiaoyan.
Current status of clinical drug-drug interactions research of innovative small molecule drugs in China
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 863-875.
|
[4] |
MENG Qiang, LIU Kexin.
Research status and prospect of transporter-mediated drug-drug interactions
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 876-888.
|
[5] |
ZHOU Han, LIU Xiaodong.
Application of physiologically based pharmacokinetic model in drug development and several questions being thought
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 889-913.
|
[6] |
SUN Bo, FU Shujun, CHEN Guiliang, LI Li.
Applications of Drug Interaction Study in New Drug Development and Regulartory Decision-making
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(10): 1095-1102.
|
[7] |
YANG Lu, WEI Bin, ZHANG Liping, BI Shanshan, LU Wei.
Response surface model to optimize the concentration range of propofol and remifentanil
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 413-420.
|
[8] |
WU Qiaoyu, YUAN Hong, LU Yao.
Evaluation of the effects of resveratrol on the activity human cytochrome P450 through combined probe method
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 426-432.
|
[9] |
SHA Bijun, ZHOU Sufeng, WANG Lu, ZHAO Yuqing, CHEN Xijing, SHAO Feng.
Methods and progress of clinical research on drug-drug interactions
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1037-1045.
|
[10] |
WEN Chunjie, ZHANG Ying, WU Lanxiang, ZHOU Honghao.
Inhibitory effect of vemurafenib on UGT1A1-mediated irinotecan metabolism
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(7): 773-777.
|
[11] |
SHAN Xiaolei, FU Shujun, GAO Guanghua, SUN Tao, WANG Qingli, YU Shanshan.
Metabolism- and transporter-mediated drug-drug interaction-overview of in vitro study and cases analysis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(10): 1165-1171.
|
[12] |
LI Li, YANG Jinbo.
Strategies of clinical drug-drug interaction studies and application progress of physiologically-based pharmacokinetic model
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(10): 1085-1091.
|
[13] |
ZHANG Jingxian, CHEN Tao, ZHANG Xiangqi, SHI Meizhi, CHEN Junjun, ZHANG Kezhi, YANG Jiao, GUO Cheng, WANG Laiyou, HAN Yonglong.
Inhibition effects of Danhong injection on three transporters in human primary hepatocytes in vitro
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(4): 389-394.
|
[14] |
HUANG Qiong, DU Jie, CHENG Shuqiao, GONG Zhicheng.
Progress of proton pump inhibitors using in cancer patients
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(10): 1179-1187.
|
[15] |
YANG Rui, XU Haisha, ZHANG Zanling, QU Jian, LI Juan, PENG Shiqi, DAI Yuxin, QU Qiang.
Effect of drug interaction on anticoagulant strength of warfarin
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(12): 1426-1431.
|